Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.
Identifieur interne : 001458 ( PubMed/Corpus ); précédent : 001457; suivant : 001459Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.
Auteurs : E. Bezard ; J M Stutzmann ; C. Imbert ; T. Boraud ; A. Boireau ; C E GrossSource :
- European journal of pharmacology [ 0014-2999 ] ; 1998.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (antagonists & inhibitors), Animals, Anticonvulsants (administration & dosage), Anticonvulsants (therapeutic use), Behavior, Animal (drug effects), Disease Models, Animal, Dopamine Agents, Dose-Response Relationship, Drug, Injections, Intravenous, Macaca fascicularis, Male, Motor Activity (drug effects), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (prevention & control), Riluzole (administration & dosage), Riluzole (therapeutic use), Sodium Channel Blockers.
- MESH :
- chemical , administration & dosage : Anticonvulsants, Riluzole.
- chemical , antagonists & inhibitors : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemical , therapeutic use : Anticonvulsants, Riluzole.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Behavior, Animal, Motor Activity.
- prevention & control : Parkinson Disease, Secondary.
- Animals, Disease Models, Animal, Dopamine Agents, Dose-Response Relationship, Drug, Injections, Intravenous, Macaca fascicularis, Male, Sodium Channel Blockers.
Abstract
Preliminary studies have shown that riluzole, a Na+ channel blocker with antiglutamatergic activity, has neuroprotective efficacy in several models of acute dopaminergic neurodegeneration. A chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model which comes closer to the slow evolution of Parkinson's disease has recently been developed in order to allow dynamic studies. The present results show that riluzole delayed the appearance of parkinsonian motor abnormalities in this dynamic model, using from 10.2 +/- 1.6 daily injections for the MPTP-treated monkeys (n = 4) to 16.5 +/- 2.0 daily injections for the MPTP + riluzole-treated monkeys (n = 4). These results strongly suggest that riluzole may be beneficial to slow down the rate of progression of Parkinson's disease.
PubMed: 9774238
Links to Exploration step
pubmed:9774238Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.</title><author><name sortKey="Bezard, E" sort="Bezard, E" uniqKey="Bezard E" first="E" last="Bezard">E. Bezard</name><affiliation><nlm:affiliation>Laboratoire de Neurophysiologie, CNRS UMR 5543, Université de Bordeaux II, France.</nlm:affiliation></affiliation></author><author><name sortKey="Stutzmann, J M" sort="Stutzmann, J M" uniqKey="Stutzmann J" first="J M" last="Stutzmann">J M Stutzmann</name></author><author><name sortKey="Imbert, C" sort="Imbert, C" uniqKey="Imbert C" first="C" last="Imbert">C. Imbert</name></author><author><name sortKey="Boraud, T" sort="Boraud, T" uniqKey="Boraud T" first="T" last="Boraud">T. Boraud</name></author><author><name sortKey="Boireau, A" sort="Boireau, A" uniqKey="Boireau A" first="A" last="Boireau">A. Boireau</name></author><author><name sortKey="Gross, C E" sort="Gross, C E" uniqKey="Gross C" first="C E" last="Gross">C E Gross</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9774238</idno><idno type="pmid">9774238</idno><idno type="wicri:Area/PubMed/Corpus">001458</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001458</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.</title><author><name sortKey="Bezard, E" sort="Bezard, E" uniqKey="Bezard E" first="E" last="Bezard">E. Bezard</name><affiliation><nlm:affiliation>Laboratoire de Neurophysiologie, CNRS UMR 5543, Université de Bordeaux II, France.</nlm:affiliation></affiliation></author><author><name sortKey="Stutzmann, J M" sort="Stutzmann, J M" uniqKey="Stutzmann J" first="J M" last="Stutzmann">J M Stutzmann</name></author><author><name sortKey="Imbert, C" sort="Imbert, C" uniqKey="Imbert C" first="C" last="Imbert">C. Imbert</name></author><author><name sortKey="Boraud, T" sort="Boraud, T" uniqKey="Boraud T" first="T" last="Boraud">T. Boraud</name></author><author><name sortKey="Boireau, A" sort="Boireau, A" uniqKey="Boireau A" first="A" last="Boireau">A. Boireau</name></author><author><name sortKey="Gross, C E" sort="Gross, C E" uniqKey="Gross C" first="C E" last="Gross">C E Gross</name></author></analytic><series><title level="j">European journal of pharmacology</title><idno type="ISSN">0014-2999</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (antagonists & inhibitors)</term><term>Animals</term><term>Anticonvulsants (administration & dosage)</term><term>Anticonvulsants (therapeutic use)</term><term>Behavior, Animal (drug effects)</term><term>Disease Models, Animal</term><term>Dopamine Agents</term><term>Dose-Response Relationship, Drug</term><term>Injections, Intravenous</term><term>Macaca fascicularis</term><term>Male</term><term>Motor Activity (drug effects)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (prevention & control)</term><term>Riluzole (administration & dosage)</term><term>Riluzole (therapeutic use)</term><term>Sodium Channel Blockers</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticonvulsants</term><term>Riluzole</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term><term>Riluzole</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Dopamine Agents</term><term>Dose-Response Relationship, Drug</term><term>Injections, Intravenous</term><term>Macaca fascicularis</term><term>Male</term><term>Sodium Channel Blockers</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Preliminary studies have shown that riluzole, a Na+ channel blocker with antiglutamatergic activity, has neuroprotective efficacy in several models of acute dopaminergic neurodegeneration. A chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model which comes closer to the slow evolution of Parkinson's disease has recently been developed in order to allow dynamic studies. The present results show that riluzole delayed the appearance of parkinsonian motor abnormalities in this dynamic model, using from 10.2 +/- 1.6 daily injections for the MPTP-treated monkeys (n = 4) to 16.5 +/- 2.0 daily injections for the MPTP + riluzole-treated monkeys (n = 4). These results strongly suggest that riluzole may be beneficial to slow down the rate of progression of Parkinson's disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9774238</PMID><DateCreated><Year>1998</Year><Month>12</Month><Day>18</Day></DateCreated><DateCompleted><Year>1998</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0014-2999</ISSN><JournalIssue CitedMedium="Print"><Volume>356</Volume><Issue>2-3</Issue><PubDate><Year>1998</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>European journal of pharmacology</Title><ISOAbbreviation>Eur. J. Pharmacol.</ISOAbbreviation></Journal><ArticleTitle>Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.</ArticleTitle><Pagination><MedlinePgn>101-4</MedlinePgn></Pagination><Abstract><AbstractText>Preliminary studies have shown that riluzole, a Na+ channel blocker with antiglutamatergic activity, has neuroprotective efficacy in several models of acute dopaminergic neurodegeneration. A chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model which comes closer to the slow evolution of Parkinson's disease has recently been developed in order to allow dynamic studies. The present results show that riluzole delayed the appearance of parkinsonian motor abnormalities in this dynamic model, using from 10.2 +/- 1.6 daily injections for the MPTP-treated monkeys (n = 4) to 16.5 +/- 2.0 daily injections for the MPTP + riluzole-treated monkeys (n = 4). These results strongly suggest that riluzole may be beneficial to slow down the rate of progression of Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bezard</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratoire de Neurophysiologie, CNRS UMR 5543, Université de Bordeaux II, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stutzmann</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Imbert</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Boraud</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Boireau</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>C E</ForeName><Initials>CE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Pharmacol</MedlineTA><NlmUniqueID>1254354</NlmUniqueID><ISSNLinking>0014-2999</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026941">Sodium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015632" MajorTopicYN="N">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007275" MajorTopicYN="N">Injections, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026941" MajorTopicYN="Y">Sodium Channel Blockers</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>10</Month><Day>17</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>10</Month><Day>17</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9774238</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001458 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001458 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:9774238
|texte= Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:9774238" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |